9. Hepatitis B (HBV) or hepatitis C (HCV). All patients must be screened for HBV and HCV up to 28 days prior to study drug start using the routine hepatitis virus laboratorial panel. Patients who test positive for HBsAg or HBcAb will be eligible if they are negative for HBV DNA; patients who test positive for anti-HCV antibody will be eligible if they are negative for HCV RNA.